GW786034 in Treating Patients With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: GW786034 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of GW786034 in treating patients with advanced solid tumors.

Key facts

Study ID

NCT00060151

Run by

Case Comprehensive Cancer Center

Starts

2002-12-01

Expected to finish

2009-06-01

Last updated by the study team

2013-09-20

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Duke Comprehensive Cancer Center — Durham, North Carolina, United States
• Case Comprehensive Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.